Deborah Panebianco

1.9k total citations
64 papers, 1.4k citations indexed

About

Deborah Panebianco is a scholar working on Hepatology, Infectious Diseases and Psychiatry and Mental health. According to data from OpenAlex, Deborah Panebianco has authored 64 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hepatology, 13 papers in Infectious Diseases and 12 papers in Psychiatry and Mental health. Recurrent topics in Deborah Panebianco's work include Hepatitis C virus research (14 papers), HIV/AIDS drug development and treatment (13 papers) and Migraine and Headache Studies (9 papers). Deborah Panebianco is often cited by papers focused on Hepatitis C virus research (14 papers), HIV/AIDS drug development and treatment (13 papers) and Migraine and Headache Studies (9 papers). Deborah Panebianco collaborates with scholars based in United States, Belgium and United Kingdom. Deborah Panebianco's co-authors include Inge De Lepeleire, Elizabeth Hand, Michael R. Goldberg, Hans Deckmyn, Jos Vermylen, Kathelijne Peerlinck, Jacqueline B. McCrea, S. Aubrey Stoch, Kevin J. Petty and Jeffrey Barrett and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Deborah Panebianco

61 papers receiving 1.4k citations

Peers

Deborah Panebianco
Michael J. Fossler United States
Dolores B. Njoku United States
Bruna Lo Sasso Italy
Jake J. Thiessen Canada
Robert J. Noveck United States
Stefano Federico Italy
Iolanda Mazzucchelli Italy
William A. Parker United Kingdom
Lin Yang China
Chiara Bellia Italy
Michael J. Fossler United States
Deborah Panebianco
Citations per year, relative to Deborah Panebianco Deborah Panebianco (= 1×) peers Michael J. Fossler

Countries citing papers authored by Deborah Panebianco

Since Specialization
Citations

This map shows the geographic impact of Deborah Panebianco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Panebianco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Panebianco more than expected).

Fields of papers citing papers by Deborah Panebianco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Panebianco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Panebianco. The network helps show where Deborah Panebianco may publish in the future.

Co-authorship network of co-authors of Deborah Panebianco

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Panebianco. A scholar is included among the top collaborators of Deborah Panebianco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Panebianco. Deborah Panebianco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Caro, Luzelena, Larissa Wenning, Hwa-ping Feng, et al.. (2019). Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. European Journal of Clinical Pharmacology. 75(5). 665–675. 10 indexed citations
2.
Wrishko, Rebecca E., Jacqueline B. McCrea, Ka Lai Yee, et al.. (2019). Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. Clinical Drug Investigation. 39(5). 441–451. 15 indexed citations
3.
Feng, Hwa-ping, Luzelena Caro, Christine Fandozzi, et al.. (2018). Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers. The Journal of Clinical Pharmacology. 58(5). 666–673. 14 indexed citations
4.
Marshall, William L., Larissa Wenning, Xiaobi Huang, et al.. (2017). Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment. European Journal of Drug Metabolism and Pharmacokinetics. 43(3). 321–329. 4 indexed citations
5.
Stroh, Mark, Xiaodong Li, Deborah Panebianco, et al.. (2012). The minimal impact of food on the pharmacokinetics of ridaforolimus. Cancer Chemotherapy and Pharmacology. 70(1). 177–182. 4 indexed citations
6.
Stroh, Mark, John Palcza, Jacqueline B. McCrea, et al.. (2012). The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus. Cancer Chemotherapy and Pharmacology. 69(5). 1247–1253. 5 indexed citations
7.
Chaitman, Bernard, Andrew P. Ho, Jason F. Rowe, et al.. (2012). A Randomized, Placebo-Controlled Study of the Effects of Telcagepant on Exercise Time in Patients With Stable Angina. Clinical Pharmacology & Therapeutics. 91(3). 459–466. 48 indexed citations
8.
Han, Tae Hyung, Rebecca Blanchard, John Palcza, et al.. (2010). The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects. PubMed. 3(4). 55–62. 9 indexed citations
9.
Chaitman, Bernard, Andrew P. Ho, Janice Rowe, et al.. (2010). THE CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST TELCAGEPANT DOES NOT REDUCE EXERCISE TOLERANCE IN PATIENTS WITH EXERCISE INDUCED MYOCARDIAL ISCHEMIA. Journal of the American College of Cardiology. 55(10). A100.E939–A100.E939. 4 indexed citations
10.
Stoch, S. Aubrey, Cynthia Gargano, J L Valentine, et al.. (2010). Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemotherapy and Pharmacology. 67(6). 1313–1321. 13 indexed citations
11.
Stoch, S. Aubrey, Stefan Zajic, Julie A. Stone, et al.. (2009). Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies. Clinical Pharmacology & Therapeutics. 86(2). 175–182. 124 indexed citations
12.
Panebianco, Deborah & Andrea Maes. (2009). Estimating time to steady state using the effective rate of drug accumulation. Pharmaceutical Statistics. 10(1). 27–33. 2 indexed citations
13.
Panebianco, Deborah, et al.. (2008). Evaluation of Methods for Estimating Time to Steady State with Examples from Phase 1 Studies. The AAPS Journal. 10(1). 141–147. 35 indexed citations
14.
Hogg, Ronald J., Ángela Delucchi, Thomas G. Wells, et al.. (2007). A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatric Nephrology. 22(5). 695–701. 24 indexed citations
15.
Majumdar, Anup, Laura Howard, Michael R. Goldberg, et al.. (2006). Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers. The Journal of Clinical Pharmacology. 46(3). 291–300. 84 indexed citations
16.
Wenning, Larissa, M. Gail Murphy, Laura P. James, et al.. (2005). Pharmacokinetics of Famotidine in Infants. Clinical Pharmacokinetics. 44(4). 395–406. 9 indexed citations
17.
Wells, Thomas G., Ronald J. Hogg, Abdullah Şakarcan, et al.. (2001). The Pharmacokinetics of Enalapril in Children and Infants with Hypertension. The Journal of Clinical Pharmacology. 41(10). 1064–1074. 39 indexed citations
18.
Olah, Timothy, et al.. (2000). Rizatriptan, a Novel 5-HT<SUB>1D/1B</SUB> Agonist for Migraine: Single- and Multiple-Dose Tolerability and Pharmacokinetics in Healthy Subjects. The Journal of Clinical Pharmacology. 40(1). 74–83. 27 indexed citations
19.
Barrett, Jeffrey S., Gail Murphy, Kathelijne Peerlinck, et al.. (1994). Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clinical Pharmacology & Therapeutics. 56(4). 377–388. 111 indexed citations
20.
Pfeiffer, Norbert, et al.. (1991). Comparative tolerability of topical carbonic anhydrase inhibitor MK-927 and its S-enantiomer MK-417. Graefe s Archive for Clinical and Experimental Ophthalmology. 229(2). 111–114. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael J. Fossler Breakdown of academic impact, for papers by Dolores B. Njoku Breakdown of academic impact, for papers by Bruna Lo Sasso Breakdown of academic impact, for papers by Jake J. Thiessen Breakdown of academic impact, for papers by Robert J. Noveck Breakdown of academic impact, for papers by Stefano Federico Breakdown of academic impact, for papers by Iolanda Mazzucchelli Breakdown of academic impact, for papers by William A. Parker Breakdown of academic impact, for papers by Lin Yang Breakdown of academic impact, for papers by Chiara Bellia
Rankless by CCL
2026